Granite Point Capital Management L.P. raised its holdings in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 60.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 80,000 shares of the biotechnology company’s stock after buying an additional 30,000 shares during the period. Granite Point Capital Management L.P.’s holdings in Five Prime Therapeutics were worth $1,754,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Oppenheimer & Co. Inc. bought a new stake in Five Prime Therapeutics during the third quarter valued at about $223,000. Dupont Capital Management Corp bought a new stake in Five Prime Therapeutics during the third quarter valued at about $341,000. Teacher Retirement System of Texas bought a new stake in Five Prime Therapeutics during the fourth quarter valued at about $221,000. Virtu KCG Holdings LLC bought a new stake in Five Prime Therapeutics during the second quarter valued at about $331,000. Finally, Voya Investment Management LLC raised its holdings in Five Prime Therapeutics by 9.5% during the second quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 1,097 shares during the period. 72.14% of the stock is currently owned by institutional investors and hedge funds.

Shares of Five Prime Therapeutics Inc (FPRX) opened at $18.73 on Tuesday. Five Prime Therapeutics Inc has a twelve month low of $17.05 and a twelve month high of $49.30. The stock has a market capitalization of $621.38, a PE ratio of -3.70 and a beta of 3.56.

A number of equities research analysts have commented on the company. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Monday, October 16th. Royal Bank of Canada raised their price target on Five Prime Therapeutics from $41.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, November 6th. BMO Capital Markets raised their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. ValuEngine cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, BidaskClub cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Three analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $64.00.

ILLEGAL ACTIVITY WARNING: “Five Prime Therapeutics Inc (FPRX) Holdings Raised by Granite Point Capital Management L.P.” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2018/02/13/five-prime-therapeutics-inc-fprx-holdings-raised-by-granite-point-capital-management-l-p.html.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.